Skip to Content

Persons with active, moderate to severe ulcerative colitis needed (MERIT-UC)

Objective

This study is being conducted to investigate the efficacy of methotrexate in treating ulcerative colitis in patients that have active, moderate to severe colitis and have failed other types of therapies.

IRB Protocol Number
COMIRB 12-1408

All Other Trials

  • Digestive
Contact
Katelyn Cowan at 303-724-7875
or Katelyn.Cowan@ucdenver.edu
Eligibility and Other Participant Information

Inclusion Criteria

  • Ages of 18-70
  • Ulcerative colitis has been diagnosed by routine criteria

At least one of the following applies:

  • Steroid dependent
  • Failed 5-ASA (mesalamine) therapy, such as Asacol®
  • Failed/lost response to infliximab (Remicade®)
  • Intolerant/unresponsive to azathioprine (Imuran) or 6-MP (Purinethol) therapy

Exclusion Criteria (partial)

  • Existing pregnancy, lactation, or planned pregnancy (men and women)

This research study includes:

  • Physical exams and blood draws
  • Taking an investigational drug weekly for up to 48 weeks
  • Recording ulcerative colitis symptoms in a diary

** Compensation is provided **

Location

  • University of Colorado Hospital (UCH)
    12605 E. 16th Ave.
    Aurora, CO 80045